These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 16360231)

  • 1. Antiviral hepatitis and antiretroviral drug interactions.
    Perronne C
    J Hepatol; 2006; 44(1 Suppl):S119-25. PubMed ID: 16360231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.
    Moreno A; Quereda C; Moreno L; Perez-Elías MJ; Muriel A; Casado JL; Antela A; Dronda F; Navas E; Bárcena R; Moreno S
    Antivir Ther; 2004 Feb; 9(1):133-8. PubMed ID: 15040545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management.
    Mauss S
    J Hepatol; 2006; 44(1 Suppl):S114-8. PubMed ID: 16356579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
    Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
    J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intolerance to and/or drug interactions of anti-HIV and anti-HVC therapy].
    Galpérine T; Merle C; de Truchis P; Bernard L; Perronne C
    Med Mal Infect; 2005 Mar; 35(3):135-40. PubMed ID: 15911183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
    Butt AA
    AIDS Read; 2003 Jul; 13(7):344-8. PubMed ID: 12889452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
    Glesby MJ; Gerber JG
    AIDS Read; 2003 Jul; 13(7):346-7. PubMed ID: 12889453
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
    Neuman MG; Monteiro M; Rehm J
    Subst Use Misuse; 2006; 41(10-12):1395-463. PubMed ID: 17002989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of the side effects of antiviral therapy].
    Vcev A
    Acta Med Croatica; 2005; 59(5):469-72. PubMed ID: 16381245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.
    Margot NA; Miller MD
    Antivir Ther; 2005; 10(2):343-8. PubMed ID: 15865229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of chronic hepatitis C in patients with HIV infection].
    Begovac J
    Acta Med Croatica; 2005; 59(5):473-8. PubMed ID: 16381246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
    Nüesch R; Ananworanich J; Srasuebkul P; Chetchotisakd P; Prasithsirikul W; Klinbuayam W; Mahanontharit A; Jupimai T; Ruxrungtham K; Hirschel B
    AIDS; 2008 Jan; 22(1):152-4. PubMed ID: 18090405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.
    Jiménez-Nácher I; García B; Barreiro P; Rodriguez-Novoa S; Morello J; González-Lahoz J; de Mendoza C; Soriano V
    J Antimicrob Chemother; 2008 Oct; 62(4):816-22. PubMed ID: 18567912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.